Shares of CVS Health Corporation (NYSE:CVS) fell $-0.47 during today’s regular trading session, a -0.62% decrease from the previous closing price of $76.42. The company’s shares traded on weaker-than-usual volume today: $5.54M shares changed hands while the stock’s average volume is 6.48M shares per day. CVS Health Corporation (CVS) has declined $6.22, or -7.57%, in the last 30 days. This year-to-date, the company’s shares have decreased $2.96, or -3.75%. Over the last 12 months, CVS’s stock price has declined $21.60, or -22.14%. The company’s 52-week range is $69.30 to $98.67.

CVS Health Corporation (CVS) Earnings Surprises

CVS Health Corporation announced its recent quarter financial results after the market close on 02/05/2017, crushing consensus estimates with both its revenue and earnings. CVS Health Corporation posted net revenue of 44.51B, beating Wall Street analysts who had forecast $44.2B. The company reported EPS of $1.17, above the consensus estimate calling for EPS of $1.10 – a positive surprise of 6.17%.

Before that, quarter ending December 2016, CVS Health Corporation also surprised analysts by beating the consensus estimate. The Wall Street forecast had projected $1.67 per share, and the company reported EPS of $1.71 – also a 2.49% positive surprise. Revenue during the period amounted to $45.97B, while analysts were anticipating $46.5B.

In the quarter ending September 2016, CVS Health Corporation delivered smaller earnings beat. Analysts, on average, were expecting $1.57 per share, and the company reported EPS of $1.59 – amounting to a positive surprise of 1.42%. Revenue during that quarter was posted at $44.62B, whereas the consensus estimate was predicting $45.29B.

The company is scheduled to announce its next quarterly financial results on 01/08/2017 after the market close. The average EPS estimate of 21 Wall Street analysts is $1.31 per share, compared to the company’s reported EPS of $1.32 per share in the year-ago quarter. Analysts are forecasting CVS Health Corporation to report revenue of about $45.39B, versus the $43.73B posted last year.

CVS Health Corporation (CVS) Consensus Estimates and Price Target

The company’s consensus rating is currently Strong Buy, with 10 analysts rating it a Strong Buy, and 7 analysts rating it with a Hold. The average 12-month price target, as forecast by analysts, is $86.77, 14.25% higher than the company’s closing price today.